Direct Answer
Health care distributors (pharmaceutical wholesalers) purchase drugs from manufacturers and distribute them to pharmacies, hospitals, and clinics. The "Big Three" -- McKesson, AmerisourceBergen (now Cencora), and Cardinal Health -- handle roughly 90% of US prescription drug distribution. Gross margins are thin (1-3%) but fee-for-service contracts and specialty drug growth support improving revenue per unit. The opioid epidemic litigation cost all three companies billions in settlement payments in the early 2020s.
Pharmaceutical Wholesale: Economics, Buy-Side, and Sell-Side
Pharmaceutical wholesalers purchase branded and generic drugs from manufacturers at wholesale acquisition cost (WAC) minus a negotiated discount, and sell them to pharmacies, hospitals, and clinics at WAC plus a mark-up (or on a fee-for-service basis). The gross margin on drug distribution is thin -- typically 1-3% of revenue -- because drug prices are set by manufacturers and the distribution function is relatively commoditized. However, absolute revenue is very large (the three major US wholesalers combined handle $600+ billion in annual revenue), making the thin margin generate substantial absolute gross profit dollars.
The industry has shifted from "buy-side" economics (wholesalers profiting from purchasing drugs at a discount and holding inventory as drug prices inflated, then selling at higher prices) toward "fee-for-service" models (fixed fees per unit distributed, regardless of drug price changes). This shift was driven by manufacturers wanting better distribution data and by payers pressuring for distribution cost transparency. Fee-for-service contracts reduce the wholesaler's exposure to generic drug price deflation (which used to destroy margins when held inventory became worth less) but also eliminate the benefit of drug price inflation in branded drugs.
Specialty pharmaceutical distribution (oncology drugs, immunology products, gene therapies) is the high-growth, higher-margin segment within drug wholesaling: specialty drugs are complex, expensive, temperature-sensitive, and require specialized handling and compliance capabilities. AmerisourceBergen/Cencora's specialty distribution business (including its acquisition of World Courier for global specialty logistics) has driven above-average margin improvement versus the commodity generics and branded drugs segment.
Opioid Epidemic Litigation and Settlement Impact
The three major US pharmaceutical wholesalers -- McKesson, AmerisourceBergen, and Cardinal Health -- were sued by states, counties, and municipalities alleging their distribution of opioid medications (particularly oxycodone and hydrocodone) to pharmacies that were dispensing drugs in suspected diversion schemes contributed to the opioid epidemic. The litigation argued that wholesalers failed to detect and report "suspicious orders" to the DEA as required by the Controlled Substances Act.
In July 2021, McKesson, AmerisourceBergen, and Cardinal Health announced a landmark settlement framework: $21 billion in total payments over 18 years ($11.4B from McKesson, $6.1B from AmerisourceBergen, $8.0B from Cardinal Health, shared against three large distributors and Johnson & Johnson which settled separately). Individual states and jurisdictions were required to opt in; most did. The settlement included compliance provisions (enhanced opioid monitoring systems) as well as payments.
The settlement payments have been progressively accounted for as charges and are mostly behind the companies as of 2023-2024, though multi-year payment obligations continue. The legal overhang created significant share price suppression in 2019-2022; its resolution has been a significant catalyst for stock recovery. Investors now focus on earnings power ex-litigation rather than the litigation itself, though the ongoing payment schedule still represents meaningful cash outflows.
Major Players: McKesson, Cencora, Cardinal Health
McKesson Corporation (MCK) is the largest US pharmaceutical distributor by revenue, with leading positions in both pharmaceutical distribution and oncology services. Its US Pharmaceutical segment distributes branded, generic, and specialty drugs to more than 40,000 customers including retail pharmacies, hospital systems, and cancer treatment facilities. McKesson's CoverMyMeds (formerly RelayHealth) electronic prior authorization platform is a strategic asset connecting prescribers, pharmacies, and payers.
Cencora (AMOR, formerly AmerisourceBergen) rebranded from AmerisourceBergen to Cencora in 2023, reflecting its expansion from a US pharmaceutical distributor to a global healthcare solutions company through acquisitions including Alliance Healthcare (European pharmaceutical distribution) and World Courier (specialty logistics). Its specialty distribution capabilities in oncology and immunology are a key competitive differentiator.
Cardinal Health (CAH) distributes pharmaceuticals and medical supplies to hospital systems, pharmacies, and physician offices. Its Pharmaceutical and Specialty Solutions segment handles drug distribution; its Global Medical Products and Distribution segment distributes medical surgical supplies. Cardinal has historically had the weakest profitability among the Big Three, partly due to its exposure to the lower-margin generic drug segment and prior management execution challenges; restructuring efforts have aimed at margin improvement.
Specialty Drug Growth and Biosimilars Opportunity
Specialty pharmaceuticals (drugs requiring special handling, administration, monitoring, or limited distribution -- typically biologics for cancer, autoimmune diseases, and rare conditions) have grown from a small fraction of drug spending to the majority of pharmaceutical expenditure growth. The per-unit revenue from specialty drug distribution is higher than generic distribution, and specialty logistics capability (cold chain, clinical support programs, patient assistance) commands premium fees.
The biosimilar opportunity represents the most significant industry tailwind for health care distributors: as patents on blockbuster biologics (adalimumab/Humira, etanercept/Enbrel, bevacizumab/Avastin) expire, biosimilar competitors enter the market at substantial discounts (20-80% below reference biologic pricing), expanding patient access. Wholesalers handling growing biosimilar volumes benefit from expanding unit volumes even as per-unit prices decline -- net revenue per drug category can rise as unit volumes grow with the expanded access that lower biosimilar prices enable.
GLP-1 receptor agonists (Ozempic, Wegovy, Mounjaro, Zepbound) for diabetes and obesity management are one of the fastest-growing pharmaceutical categories. These drugs are distributed through the pharmaceutical wholesale channel; their high price per unit and extremely high demand volumes represent a meaningful growth driver for all three major US wholesalers.
Investment Considerations: Post-Litigation Rerating, GLP-1 Tailwind, and Capital Allocation
Health care distributors trade at below-market P/E multiples (12-18x forward earnings) reflecting the thin gross margin nature of the business, historical litigation overhang, and generic drug price deflation concerns. Post-settlement resolution has driven meaningful multiple expansion as litigation risk is now quantified and declining. McKesson and Cencora have generated very strong total returns since settlement resolution.
Share buybacks are the primary capital allocation tool: the limited organic investment need in distribution businesses (minimal capex, working capital efficiency-focused) leaves substantial free cash flow for buyback programs. McKesson has reduced its share count by 40%+ over a decade, amplifying per-share earnings growth well above revenue growth. This "capital allocation compounding" is a major driver of healthcare distributor investment returns over full cycles.
Revenue quality is a key differentiator: McKesson and Cencora's shift toward higher-margin specialty distribution and lower-margin but growing generic volume has improved earnings quality versus the pure branded drug distribution model. Investors assess earnings "mix shift" (branded versus generic versus specialty) as an indicator of future margin trajectory.
FAQ
What does a pharmaceutical distributor actually do?
Pharmaceutical distributors (wholesalers) are the logistics infrastructure between drug manufacturers and the pharmacies, hospitals, and clinics that dispense drugs to patients. They purchase drugs from manufacturers (Pfizer, Merck, Lilly, and thousands of generic manufacturers), warehouse them in temperature-controlled distribution centers, and deliver them to 40,000+ customers within 24-48 hours. They also provide services like pharmaceutical return processing, inventory management, track-and-trace compliance (DSCSA serialization requirements), and specialty drug handling. Without wholesalers, a typical pharmacy would need to manage direct relationships with hundreds of drug manufacturers -- the distributor provides one-order access to the entire drug catalog.
How did the opioid settlement affect McKesson, AmerisourceBergen, and Cardinal Health?
The $21 billion settlement (announced July 2021, finalized 2022) required the Big Three to pay state, local, and tribal governments over 18 years for their role in distributing opioids to pharmacies that were filling suspicious prescription volumes. The companies also agreed to enhanced monitoring systems for suspicious opioid orders. The settlement removed the largest single litigation risk from all three companies (hundreds of individual state/county lawsuits were consolidated into the global framework). Share prices, suppressed by years of litigation uncertainty, recovered substantially after settlement. Annual cash settlement payments continue through the late 2030s, but the amounts are predictable and have been largely accounted for in company financials.
Why are health care distributor margins so thin?
Pharmaceutical distribution margins are thin (1-3% gross margin) because drug prices are set by manufacturers, distribution is largely a logistics function, and competition among the Big Three is intense. The product itself (a drug) is identical regardless of who distributes it; a pharmacy choosing a distributor makes the decision on service (delivery reliability, order system), credit terms, and price -- competitive pressure drives margins to minimum sustainable levels. What makes the business valuable despite thin margins is scale: $600+ billion in combined annual revenue means that even a 1-2% gross margin generates billions in absolute gross profit, while the capital-light operating model produces strong free cash flow. The industry has also shifted to fee-for-service contracts that provide more predictable revenue than buy-side margin models.
What is the biosimilar opportunity for pharmaceutical distributors?
Biosimilars are biologic drugs (produced from living cells) that are highly similar to reference biologics whose patents have expired, approved by the FDA as biosimilar to the reference product. They typically launch at 20-80% discounts to the reference drug, dramatically expanding patient access. When Humira biosimilars launched in 2023 (adalimumab is the world's best-selling drug), distributor unit volumes in that drug class expanded substantially as more patients could access treatment at lower cost. For distributors, biosimilar adoption increases the number of prescriptions filled (good for volume), though the per-prescription revenue declines -- net revenue per drug category can rise or fall depending on the volume elasticity. The overall trend toward greater biologic drug use and biosimilar penetration is a long-term volume tailwind for pharmaceutical distribution.